Literature DB >> 16779712

Sacral resection for recurrent rectal cancer: analysis of morbidity and treatment results.

Genevieve B Melton1, Philip B Paty, Patrick J Boland, John H Healey, Salvatore G Savatta, Jorge E Casas-Ganem, José G Guillem, Martin R Weiser, Alfred M Cohen, Bruce D Minsky, W Douglas Wong, Larissa K Temple.   

Abstract

PURPOSE: Composite sacropelvic resection for locally advanced recurrent rectal cancer is a high-risk procedure that benefits select patients. We reviewed our recent institutional experience to evaluate case selection, morbidity, and outcomes.
METHODS: Between 1987 and 2004, 29 patients underwent composite resection for recurrent locoregional rectal cancer (17 females; median age, 60 years). Clinicopathologic indicators were evaluated as indicators of survival by log-rank test and Cox proportional hazards model.
RESULTS: Of 29 total patients, 27 (93 percent) received radiotherapy with their previous surgery (n = 10; 34 percent) or before sacrectomy (n = 17; 59 percent), and 12 (41 percent) received intraoperative therapy. Sacral resections were performed at S2/S3 (55 percent) or S4/S5 (45 percent) using anterior (41 percent) or combined anterior-posterior approach (59 percent), with adherence to (62 percent) or cortical invasion in (38 percent) the sacrum. A majority of those who had undergone previous abdominoperineal resection had total exenteration (9/13), whereas most patients who had undergone a previous sphincter-preserving procedure had abdominoperineal resection (12/16) and none had exenteration. Pedicle flaps (omental, 11; abdominal rectus, 7) often were used. A median of five (range, 1-33) units of blood was given intraoperatively. Transfusions were associated with previous abdominoperineal resection (P < 0.03), correlating strongly with postoperative morbidity (P < 0.02). There were 33 complications in 17 (59 percent) patients, most commonly perineal wound breakdown (9 (31 percent)) and pelvic abscess (5 (17 percent)). Median hospital stay was 18 (range, 7-56) days, significantly longer in patients with previous abdominoperineal resection (P < 0.02) or postoperative morbidity (P < 0.03). The only postoperative death was from pelvic sepsis. Resection was complete (R0) in 18 patients (62 percent), with microscopically positive margins (R1) in 10 (34 percent) and grossly positive margins (R2) in 1 (3 percent). Two-year and five-year recurrence rates were 47 and 85 percent, respectively; disease-specific survival was 63 and 20 percent, respectively. Less transfusion (P = 0.03), R0 resection (P = 0.005), lack of anterior organ involvement (P = 0.02), and absence of cortical bone invasion (P < 0.001) were associated with better survival on univariate analysis; original colorectal cancer stage was not.
CONCLUSIONS: Sacrectomy for rectal cancer is a high-risk procedure that can achieve clear resection margins with low mortality in select patients. This procedure has a low cure rate but may provide local disease control with acceptable morbidity.

Entities:  

Mesh:

Year:  2006        PMID: 16779712     DOI: 10.1007/s10350-006-0563-9

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  23 in total

1.  En Bloc Resection with Partial Sacrectomy Helps to Achieve R0 Resection in Locally Advanced Rectal Cancer, Experience from a Tertiary Cancer Center.

Authors:  Nizamudheen M Pareekutty; Satheesan Balasubramanian; Sachin Kadam; Dipin Jayaprakash; Basavaraj Ankalkoti; Sangeetha Nayanar; Geetha Muttath; Bindu Anilkumar
Journal:  Indian J Surg Oncol       Date:  2019-01-09

2.  Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall.

Authors:  I Shaikh; W Aston; G Hellawell; D Ross; S Littler; D Burling; M Marshall; J M A Northover; A Antoniou; J T Jenkins
Journal:  Tech Coloproctol       Date:  2014-11-08       Impact factor: 3.781

3.  [Locally recurrent rectal cancer].

Authors:  A Troja; H R Raab
Journal:  Chirurg       Date:  2010-10       Impact factor: 0.955

Review 4.  Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer.

Authors:  Young Seok Seo; Mi-Sook Kim; Hyung-Jun Yoo; Won-Il Jang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 5.  [Therapy of locally recurrent rectal carcinoma].

Authors:  H G Hempen; H R Raab
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

6.  Locally recurrent colorectal cancer: results of surgical therapy.

Authors:  M Kruschewski; M Ciurea; S Lipka; S Daum; L Moser; B Meyer; J Gröne; J Budczies; H J Buhr
Journal:  Langenbecks Arch Surg       Date:  2012-06-28       Impact factor: 3.445

7.  Interstitial permanent implantation of 125I seeds as salvage therapy for re-recurrent rectal carcinoma.

Authors:  Jun Jie Wang; Hui Shu Yuan; Jin Na Li; Wei Juan Jiang; Yu Liang Jiang; Su Qing Tian
Journal:  Int J Colorectal Dis       Date:  2008-12-16       Impact factor: 2.571

8.  Radical redo surgery for local rectal cancer recurrence improves overall survival: a single center experience.

Authors:  Paulus Schurr; Edda Lentz; Suzette Block; Jussuf Kaifi; Helge Kleinhans; Guellue Cataldegirmen; Asad Kutup; Claus Schneider; Tim Strate; Emre Yekebas; Jakob Izbicki
Journal:  J Gastrointest Surg       Date:  2008-04-30       Impact factor: 3.452

9.  Intraoperative bleeding and haemostasis during pelvic surgery for locally advanced or recurrent rectal cancer: a prospective evaluation.

Authors:  V A Bonello; A Bhangu; J E F Fitzgerald; S Rasheed; P Tekkis
Journal:  Tech Coloproctol       Date:  2014-06-03       Impact factor: 3.781

10.  Laparoscopic abdominosacral composite resection for locally advanced primary rectal cancer.

Authors:  G L Williams; S Gonsalves; D Bandyopadhyay; P M Sagar
Journal:  Tech Coloproctol       Date:  2008-11-18       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.